

Appointment of A/Prof Carolyn Ellaway as Chief Medical Officer

Highlights:

- **Associate Professor Carolyn Ellaway appointed as Neurotech Chief Medical Officer (CMO)**
- **A/Prof Ellaway is an internationally recognised clinical geneticist and was the lead Investigator on the Company's successful Phase I/II Rett Syndrome clinical trial**
- **The part-time role will include key opinion leader engagement along with overseeing the development and execution of regulatory and clinical trial strategies**

Neurotech International Limited (ASX: NTI) ('Neurotech', 'NTI' or 'the Company') a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announces the appointment of Associate Professor Carolyn Ellaway as the Company's first Chief Medical Officer (CMO), commencing 1 August 2024.

A/Prof Ellaway graduated from Melbourne University in 1991 and trained in Paediatrics and Clinical Genetics in Sydney and London. She is a Fellow of the Royal Australasia College of Paediatrics and a Clinical Associate Professor with Sydney University. Carolyn currently consults at The Children's Hospital at Westmead, and Sydney Children's Hospital, Randwick. She also provides a private clinical genetics service for children at Lumina Kids' Brain & Mind Clinic in Lindfield.

Her area of expertise is the diagnosis and management of children with a wide range of rare genetic disorders including mitochondrial and lysosomal storage disorders, Rett syndrome and related disorders. Associate Professor Ellaway has published over 100 peer reviewed papers and book chapters.

Associate Professor Ellaway commented "I am delighted to be appointed the inaugural CMO of Neurotech and certainly look forward to working with the Company to expedite our clinical and regulatory programs for NTI164, which hold significant potential across a range of paediatric neurological disorders, including Rett Syndrome, where I was the Principal Investigator on the trial and observed significant improvements in my patients after just 12 weeks of treatment."

Dr Thomas Duthy, Executive Director of Neurotech International said "We warmly welcome A/Prof Ellaway to Neurotech. As a leading paediatrician and clinical geneticist of significant international standing, she will provide very valuable clinical expertise and oversight to the Company as we continue the development of NTI164."

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

Further Information

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0) 402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

About NTI164

NTI164 is a proprietary drug formulation derived from a unique cannabis strain with low THC ($M < 0.3\%$) and a novel combination of cannabinoids including CBDA, CBC, CBDP, CBDB and CBN. NTI164 has been exclusively licenced for neurological applications globally. Pre-clinical studies have demonstrated a potent anti-proliferative, anti-oxidative, anti-inflammatory and neuro-protective effects in human neuronal and microglial cells. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.